PACB:NASDAQ, Pacific Biosciences of California, Inc.

Why PACB stock fell on November 2

Pacific Biosciences of California, Inc. fell 10.2% on Monday, November 2, 2026, on 9,086,116 shares. No headline about PACB came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.

PACB stock overview

Pacific Biosciences of California, Inc. (PACB:NASDAQ) closed at $2.55 on November 4, 2026, up 4.51% on the day. The stock trades 25.9% below its 52-week high of $3.44 and 138.3% above its 52-week low of $1.07. Over the past year, it gained 32.8%. Pacific Biosciences of California, Inc. is part of the Capital Goods sector (Biotechnology: Laboratory Analytical Instruments).

Key figures

Price
$2.55
Day change
+4.51%
Volume
20,916,432
Average volume
12,103,378
Market cap
792M+
52-week range
$1.07 – $3.44
50-day average
$1.87
200-day average
$1.61

Price action over the past year

In 252 trading sessions since November 4, 2025, PACB closed higher on 114 days (45%). Its best day was September 30, 2026 (+29.51%) and its worst was October 8, 2026 (-15.44%). The stock moved 10% or more in a single session 21 times.

Recent signals

PACB news

About Pacific Biosciences of California, Inc.

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes biochemical sequencing reactions. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distributors in Asia, the Middle East, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.

Similar stocks

Find more stocks like PACB with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.